Ignite Creation Date:
2024-05-06 @ 12:31 PM
Last Modification Date:
2024-10-26 @ 1:00 PM
Study NCT ID:
NCT03787602
Status:
RECRUITING
Last Update Posted:
2023-03-02
First Post:
2018-12-06
Brief Title:
Navtemadlin KRT-232 With or Without Anti-PD-1Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
Sponsor:
Kartos Therapeutics Inc
Organization:
Kartos Therapeutics Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-03-19
Start Date Type:
ACTUAL
Primary Completion Date:
2024-11
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-08
Completion Date Type:
ESTIMATED
First Submit Date:
2018-12-06
First Submit QC Date:
December 21 2018
Study First Post Date:
2018-12-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-02-28
Last Update Post Date:
2023-03-02
Last Update Post Date Type:
ACTUAL